Gainers

• ProKidney (NASDAQ:PROK) shares rose 501.8% to $3.65 during Tuesday's regular session. The market value of their outstanding shares is at $78.5 million.
• ENDRA Life Sciences (NASDAQ:NDRA) shares rose 112.18% to $7.33. The market value of their outstanding shares is at $2.5 million.
• ZyVersa Therapeutics (NASDAQ:ZVSA) stock moved upwards by 72.54% to $1.14. The market value of their outstanding shares is at $3.1 million.
• SeaStar Medical Holding (NASDAQ:ICU) shares increased by 47.59% to $0.81. The company's market cap stands at $8.8 million.
• Rallybio (NASDAQ:RLYB) shares moved upwards by 37.39% to $0.47. The market value of their outstanding shares is at $14.1 million.
• Moleculin Biotech (NASDAQ:MBRX) stock rose 33.48% to $0.52. The market value of their outstanding shares is at $5.4 million.

Losers

• Pelthos Therapeutics (AMEX:PTHS) stock declined by 26.1% to $19.18 during Tuesday's regular session. The company's market cap stands at $17.1 million.
• BioSig Technologies (NASDAQ:BSGM) stock declined by 21.64% to $9.05. The company's market cap stands at $315.2 million.
• Mustang Bio (NASDAQ:MBIO) shares declined by 16.93% to $2.77. The company's market cap stands at $14.6 million.
• NewGenIvf Group (NASDAQ:NIVF) stock declined by 16.81% to $0.72. The market value of their outstanding shares is at $3.7 million.
• GT Biopharma (NASDAQ:GTBP) stock fell 11.06% to $1.93. The market value of their outstanding shares is at $6.8 million.
• Unity Biotechnology (NASDAQ:UBX) stock fell 10.82% to $0.27. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.